document incorporate reference write oral statement company make time time contain certain forwardlooking statement meaning section security act section securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty table content include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing company goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year possible predict identify factor include limited follow new government law regulation health care reform initiatives united states state federal level country change fda foreign regulatory approval process cause delay approve prevent approval new product iii tax change phase tax benefit heretofore available united states certain foreign country new law regulation judicial decision affect pricing marketing jurisdiction change intellectual property law competitive factor new product develop competitor low price superior performance feature competitive company current product generic competition company product mature patent expire product iii technological advance patent attain competitor problem licensor supplier distributor business combination company competitor major customer difficulty delay inherent product development manufacturing sale product appear promise development fail reach market approve additional indication number reason include efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture failure product achieve maintain commercial viability iii seizure recall pharmaceutical product force closing manufacture plant failure obtain imposition limitation use loss patent intellectual property right failure company vendor supplier comply current good manufacturing practice application regulation quality assurance guideline lead temporary manufacturing shutdown product shortage delay product manufacture manufacturing distribution problem include change manufacture production site manufacturing capacity regulatory requirement change type product produce biologic physical limitation impact continuous supply legal difficulty include lawsuit claim proceeding investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition include intellectual property dispute adverse decision litigation include product liability commercial case iii inability obtain adequate insurance respect type liability recall pharmaceutical product force closing manufacture plant failure fulfill obligation supply contract government customer result liability government investigation include relate wholesaler inventory financial restatement product pricing promotion vii claim assert violation security antitrust federal state pricing law viii environmental health safety matter tax liability assurance increase scope matter future lawsuit claim proceeding investigation material increase pricing pressure worldwide include rule practice manage care group institutional governmental purchaser judicial decision governmental law regulation relate medicare medicaid healthcare reform potential impact importation legislative pharmaceutical reimbursement pricing general fluctuation buy pattern inventory level major distributor retail chain trade buyer result seasonality pricing wholesaler buying decision include effect incentive offer company wholesaler inventory management policy include workdown change wholesaler inventory level factor great expect cost difficulty include unanticipated effect difficulty acquisition disposition event include obtain regulatory approval connection evolve business strategy legal defense cost insurance expense settlement cost risk adverse decision relate litigation change advertise promotional spend category spending affect sale change product mix affect margin table content change company structure operation revenue cost staff efficiency result acquisition divestiture merger alliance restructuring strategic initiative economic factor company control change business economic condition include limited change interest rate fluctuation foreign currency exchange rate change business political economic condition political social instability military armed conflict nationalization asset debt payment moratorium restriction commerce actual threaten terrorist attack united states part world relate military action change accounting standard promulgate fasb sec aicpa require adjustment financial statement capacity efficiency reliability security potential breakdown invasion destruction interruption information system reliance company vendor partner party meet contractual regulatory obligation relation arrangement company result clinical study relate company competitor product company believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date company undertake obligation release publicly revision forwardlooke statement result new information future event table content item quantitative qualitative disclosure market risk company expose market risk change currency exchange rate interest rate reduce risk company enter certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument manage consolidated basis efficiently net exposure advantage natural offset derivative financial instrument speculative purpose gain loss hedge transaction offset gain loss underlying exposure hedge ineffective portion hedge report earning occur foreign exchange option contract forward contract hedge anticipate transaction company primary foreign currency exposure relation dollar euro japanese yen canadian dollar mexican peso table summarize company outstanding foreign exchange contract december fair value foreign exchange contract base yearend currency rate blackschole model case option contract fair value option contract forward contract view relation fair value underlie hedged transaction overall reduction exposure adverse fluctuation foreign currency exchange rate weight average notional fair strike price value maturity dollar million currency rate foreign exchange forwards australian dollar british pound canadian dollar euro polish zloty swedish krona swiss franc option contract japanese yen total contract december company hold option forward exchange contract maturity date notional amount fair value maturity date express table notional fair value year maturity million million december company hold option contract aggregate notional fair value million million respectively option company right buy japanese yen specify rate company hold forward contract aggregate notional million fair value forward contract million record current liability contract primarily relate exposure euro canadian dollar australian dollar company obligate settle forward contract base specify contract rate december balance defer net aftertax loss option forward contract include accumulate comprehensive income million million estimate reclassify earning month year end december impact hedge ineffectiveness earning loss million additionally company use forward contract offset exposure certain currency asset liability forward contract designate hedge change fair value derivative recognize earning occur december company record loss million relate forward exchange contract qualify hedge accounting treatment december company hold option forward exchange contract aggregate notional fair value million million respectively contract primarily relate exposure euro japanese yen canadian dollar australian dollar table content addition foreign exchange hedge contract note company use foreign exchange forward contract hedge foreign currency denominate monetary asset liability primary objective foreign exchange forward contract protect dollar value foreign currency denominate monetary asset liability effect volatility foreign exchange occur prior receipt settlement dollar foreign currency denominate monetary asset liability primarily denominate japanese yen euro forward contract designate hedge mark market incomeexpense notional fair value foreign exchange forward contract december million million respectively company use derivative instrument interest rate risk management policy derivative instrument include interest rate swap subject fairvalue hedge accounting treatment company execute fix float interest rate swap convert billion company fix rate debt pay variable rate debt year end december company recognize net reduction interest expense million reflect benefit lower float rate obtain swap agreement sfas require revaluation fair value swap contract underlie debt hedge swap contract underlie debt revalue result increase noncurrent asset million shortterm liabilitie million longterm debt million increase noncurrent asset longterm debt million december respectively swap contract generally hold maturity speculative purpose follow table summarize interest rate swap outstanding december notional underlie variable rate interest rate contract debt receive maturity fair value dollar million swap associate month note libor swap associate month note libor swap associate month note libor swap associate month note libor swap associate month note libor swap associate month note libor december company hold interest rate swap contract notional value million fair value million estimate change interest rate structure material impact company consolidate financial position result operation cash flow company million million longterm debt outstanding december respectively item financial statementsnote shortterm borrowing longterm debt note financial instrument additional information company maintain cash cash equivalent marketable security financial institution order limit exposure financial institution financial institution headquarter primarily north america europe table content bristolmyers squibb company consolidate statement earning million share datum item financial statement supplementary datum year end december earning net sale cost product sell marketing sell administrative advertising product promotion research development acquire inprocess research development provision restructure item net litigation charge net gain sale businessesproduct line asset impairment charge investment imclone equity net income affiliate expense net total expense earning continue operation minority interest income taxis provision income taxis minority interest net taxis earning continue operation discontinue operation net earning net gain disposal net earning earning common share basic earning continue operation discontinue operation net earning net gain disposal net earning dilute earning continue operation discontinue operation net earning net gain disposal net earning average common share outstanding basic dilute dividend declare common share accompany note integral financial statement table content bristolmyers squibb company consolidate statement comprehensive income retain earning dollar millions comprehensive income net earning comprehensive income foreign currency translation net tax benefit defer loss derivative qualify hedge net tax liability tax benefit minimum pension liability adjustment net tax benefit available sale security net tax liability total comprehensive income comprehensive income retain earning retain earning january net earning cash dividend declare zimmer common stock dividend retain earning december accompany note integral financial statement table content bristolmyers squibb company consolidate balance sheet dollar million december asset current asset cash cash equivalent marketable security receivables net allowance inventory include consignment inventory defer income taxis net valuation allowance prepaid expense total current asset property plant equipment net goodwill intangible asset net deferred income taxis net valuation allowance asset total asset liability current liability shortterm borrowing account payable accrue expense accrue rebate return foreign income taxis payable dividend payable accrue litigation liability defer revenue consign inventory total current liability liabilitie longterm debt total liability commitment contingency stockholder equity prefer stock convertible series authorize million share issue outstanding liquidation value share common stock par value share authorize billion share million issue million issue capital excess par value stock restrict stock accumulate comprehensive loss retain earning cost treasury stock million common share million total stockholder equity total liability stockholder equity accompany note integral financial statement table content bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity depreciation amortization defer income tax benefitexpense litigation settlement expense provision restructure item gain sale businessesproduct line include discontinue operation acquire inprocess research development loss gain disposal property plant equipment investment company undistribute earningslosse affiliate net unfunded pension expense impairment charge asset writeoff change operate asset liability receivables inventory prepaid expense asset defer revenue consign inventory litigation settlement payment account payable accrue expense product liability foreign income taxis payable liability net cash provide operating activity cash flow invest activity purchase net sale maturity marketable security addition property plant equipment capitalize software proceed disposal property plant equipment investment company proceed sale businessesproduct line imclone milestone payment purchase acordis specialty fibre purchase trademark patent license business investment company divestiture acquisition cost net cash investing activity cash flow financing activity shortterm borrowing net repayment longterm debt borrowing longterm debt repayment issuance common stock stock plan purchase treasury stock dividend pay net cash financing activity effect exchange rate cash increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral financial statement table content bristolmyers squibb company note consolidated financial statement note accounting policy basis consolidation consolidated financial statement include account bristolmyer squibb company bms company bristolmyers squibb control majority own subsidiary intercompany balance transaction eliminate certain prior year amount reclassify conform current year presentation use estimate preparation financial statement conformity generally accept accounting principle gaap require use estimate assumption affect report amount asset liability disclosure contingent asset contingent liability date financial statement report amount revenue expense report period significant assumption employ estimate determine value intangible asset restructuring charge accrual sale rebate return accrual legal contingency tax asset tax liability estimate apply revenue recognition policy accounting retirement postretirement benefit include actuarial assumption actual result differ estimate result revenue recognition company recognize revenue substantially risk reward ownership transfer customer case certain sale nutritional healthcare segment certain nonus business pharmaceutical segment revenue recognize date receipt purchaser revenues reduce time sale reflect expect return estimate base historical experience additionally provision time sale discount rebate estimate sale allowance base historical experience update change fact circumstance appropriate provision record reduction revenue case sale wholesaler result incentive excess wholesaler ordinary course business inventory level time understand agreement course deal consistent business practice company extend incentive base level excess inventory connection future purchase time incentive cover substantially vary directly wholesaler cost carry inventory excess wholesaler ordinary course business inventory level substantially risk reward ownership transfer shipment accordingly sale account consignment model determination sale wholesaler meet forego criterion involve evaluation variety factor number complex judgment consignment model company recognize revenue shipment product shipment product company invoice wholesaler record defer revenue gross invoice sale price classifie inventory hold wholesaler consignment inventory company cost inventory company recognize revenue consignment inventory long subject incentive arrangement later inventory sell wholesaler customer firstin firstout fifo basis sale rebate return accrual medicaid rebate accrual million million december respectively woman infant child wic rebate accrual million million respectively manage healthcare rebate contractual discount accrual million million december respectively rebate accrual establish period relate revenue recognize result reduction sale establishment liability include accrue liability accrual record base estimate proportion record revenue result rebate return prime vendor chargeback accrual establish similar manner record reduction account receivable million million december respectively income taxis provision income taxis determine asset liability approach accounting income taxis approach defer taxis represent future tax consequence expect occur report amount asset liability recover pay provision income taxis represent income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis company asset liability adjust change tax rate tax law change enact valuation allowance record reduce defer tax asset likely tax benefit realize december company approximately billion undistributed earning foreign subsidiary company accrue provision million estimate deferred taxis fourth quarter anticipation repatriate approximately billion earning pursuant american job creation act ajca taxis table content bristolmyers squibb company note consolidated financial statement continue note accounting policy continue provide balance undistribute earning approximately billion company invest expect invest undistributed earning permanently offshore future earning repatriate united states company determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide ajca provide temporary percent dividend receive deduction certain cash distribution earning foreign subsidiary deduction result federal tax rate approximately repatriate earning assume marginal federal tax rate earning qualify deduction repatriate earning reinveste united states pursuant domestic reinvestment plan approve company chief executive officer board director january department treasury issue guideline permit investment plan company expect meet requirement criterion qualify deduction provision ajca require clarification address coming month treasury congress company estimate tax cost relate repatriation december base tax law effect extent tax law guidance change estimate revise company estimate revise result change companys factual assumption occur guidance financial accounting standard board fasb staff position fsp application fasb statement accounting income taxis tax deduction qualified production activity provide american job creation act deduction treat special deduction describe statement financial accounting standard sfas special deduction affect defer tax asset liability exist enactment date impact deduction report period deduction claim company tax return company establish liability possible assessment tax authority result know tax exposure amount represent reasonable provision taxis ultimately expect pay need adjusted time information know cash cash equivalent cash equivalent primarily highly liquid investment original maturity month time purchase record cost approximate fair value marketable security company account marketable security accordance sfas account certain investment debt equity security company determine appropriate classification marketable security availableforsale time purchase december company investment marketable security report fair value unrealize gain loss report component accumulate comprehensive income loss stockholder equity amortize cost debt security adjust amortization premium accretion discount date purchase maturity amortization include interest income addition deduction coupon interest earn investment company follow investment manager method determine cost basis computing realize gain loss sale available forsale security average cost method realize gain loss include income expense inventory valuation inventory generally state average cost excess market capital asset depreciation expenditure addition renewal improvement capitalize cost depreciation generally compute straightline method base estimate useful life relate asset estimate useful life major class depreciable asset year building year machinery equipment fixture company periodically evaluate current event circumstance indicate carry value depreciable asset recoverable table content bristolmyer squibb company note consolidated financial statement continue note accounting policy continue impairment longlive asset effective january company adopt provision sfas accounting impairment longlive asset adoption sfas material effect consolidated financial statement company sfas establish accounting impairment longlive tangible intangible asset goodwill disposal segment business pursuant sfas company periodically evaluate current fact circumstance indicate carry value depreciable asset hold recoverable circumstance determine exist estimate undiscounted future cash flow produce longlived asset appropriate grouping asset compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount value estimate future cash flow company report asset dispose low carrying value estimate net realizable value capitalize software certain cost obtain internal use software significant system project capitalize amortize estimate useful life software range year cost obtain software project significant expense incur capitalize software net accumulate amortization include asset million million december respectively amortization expense million million million year end december respectively investment january company adopt fasb interpretation fin interpretation consolidation variable interest entity interpretation arb fin clarifie application accounting research bulletin arb consolidated financial statement certain entity equity investor characteristic control financial interest sufficient equity risk entity finance activity additional subordinate financial support party entity know variable interest entity vie fasb issue revision fin fin december fin effective interim period end march new exist vie adoption fin effect company financial statement entity meet definition vie fin company account entity provision accounting research bulletin arb consolidated financial statement amend sfas consolidation majorityowne subsidiary require company consolidate majority own subsidiary ability exercise control company account own company ability exercise significant influence equity method accounting company share net income loss equity investment include equity net income affiliate consolidate statement earning company periodically review equity investment impairment adjust investment fair value decline market value deem temporary company record asset impairment charge million otherthantemporary decline market value imclone system incorporate imclone longterm investment security comprise marketable equity security security investment market value readily available include asset marketable equity security classify availableforsale report fair value fair value base quote market price end report period security investment market value readily available carry cost unrealize gain loss report net relate tax effect component accumulate comprehensive income loss stockholder equity sell time sale gain loss calculate specific identification method recognize incomeexpense loss recognize income decline market value deem temporary goodwill intangible asset company adopt sfas goodwill intangible asset january certain provision adopt july respect amortization goodwill arise acquisition june sfas address initial recognition measurement intangible asset acquire outside business combination recognition measurement goodwill intangible asset subsequent acquisition sfas goodwill long amortize subject annual impairment test table content bristolmyers squibb company note consolidated financial statement continue note accounting policy continue accordance sfas goodwill test impairment adoption new standard annually sfas require goodwill test impairment twostep process step identify potential impairment second step measure impairment loss goodwill deem impaired carrying reporting unit goodwill exceed estimate fair value company complete goodwill impairment assessment indicate impairment goodwill intangible asset consist patent trademark technology license amortize straightline basis useful life range year sfas require indefinitelive intangible asset test impairment onestep process consist comparison fair value carry value intangible asset intangible asset deem impaired net book value exceed estimate fair value intangible asset evaluate impairment accordance sfas describe impairment longlive asset restructure downsize streamline operation rationalize manufacture facility company periodically record restructuring charge result company estimate judgment future plan include future termination benefit exit cost approve incur actual result vary estimate result adjustment earning product liability accrual product liability record undiscounted basis probable liability incur liability reasonably estimate base exist information accrual adjust periodically assessment effort progress additional information available receivables relate insurance thirdparty recovery product liability record undiscounted basis probable recovery realize classified reduction litigation charge consolidate statement earning contingency normal course business company subject contingency legal proceeding claim arise business cover wide range matter include product liability environmental liability tax matter accordance sfas accounting contingency company record accrual contingency probable liability incur loss reasonably estimate discussion contingency reference note income taxis note legal proceeding contingency derivative financial instrument derivative financial instrument company principally management interest rate foreign currency exposure company hold issue derivative financial instrument speculative purpose company record derivative instrument balance sheet fair value change derivative fair value recognize earning specific hedge criterion meet derivative designate fair value hedge change fair value derivative hedge item attributable hedge risk recognize consolidated statement earning derivative designate cash flow hedge effective portion change fair value derivative record comprehensive income loss subsequently recognize consolidated statement earning hedge item affect earning cash flow classify consistent underlying hedged item purchase foreign currency option entire change fair value include measurement hedge effectiveness cash flow hedge ineffective portion change fair value cash flow hedge recognize charge credit earning company designate assign derivative hedge forecast transaction specific asset specific liability hedge asset liability sell extinguish forecast transaction hedge long expect occur company immediately recognize gain loss designate hedge financial instrument consolidate statement earning shipping handling cost company typically charge customer shipping handle cost shipping handling cost charge include marketing sell administrative expense million million million respectively table content bristolmyers squibb company note consolidated financial statement continue note accounting policy continue advertising cost advertising cost expense incur advertising expense million million million respectively milestone payment company time time enter strategic alliance party company right develop manufacture market andor sell pharmaceutical product right own party result alliance company obligate payment alliance partner contingent achievement certain predetermine criterion milestone achieve prior marketing approval product payment expense research development product approval additional milestone capitalize amortize cost product sell remain useful life asset capitalize milestone payment test recoverability event change circumstance indicate carrying amount recoverable acquire inprocess research development fair value inprocess research development acquire business combination determine independent appraisal base present value research project project cash flow income approach utilize consistent guidance practice aid asset acquire business combination research development activity focus software electronic device pharmaceutical industry issue american institute certify public accountant future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent determine fair value research project expect revenue adjust technical risk completion result cash flow discount rate approximating company weight average cost capital acquire inprocess research development expense incurred underlying product receive regulatory approval future alternative use addition cost nonrefundable relate acquisition licensing product receive regulatory approval market alternative future use charge earning incur earning share basic earning common share compute weightedaverage number share outstanding year dilute earning common share compute weightedaverage number share outstanding year plus incremental share outstanding assume exercise dilutive stock option restrict stock convertible instrument foreign currency translation net asset company foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation adjustment account include comprehensive income stock compensation plan currently company apply accounting principle board apb opinion accounting stock issue employee relate interpretation accounting stockbase compensation plan disclose pro forma net income relate pro forma income share information accordance sfas accounting stockbase compensation sfas accounting stockbase compensation coststransition disclosure company recognize compensation expense stock option grant plan exercise price option date grant equal fair market value date grant restrict stock company recognize compensation expense straightline basis period restriction expire table content bristolmyer squibb company note consolidated financial statement continue note accounting policy continue follow table summarize company result pro forma basis record compensation expense base fair value grant date award plan consistent methodology prescribe sfas dollar million net earning share datum report total stockbase employee compensation expense include report net income net relate tax effect total stockbase employee compensation expense determine fair value base method award net relate tax effect pro forma basic earning share report pro forma diluted earning share report pro forma option relate discontinued operation impact basic diluted earning share note stockholder equity additional information recently issue accounting standard december fasb issue revise sfas sfas sharebase payment standard eliminate ability account share base compensation transaction intrinsic valuebase method accounting principle board opinion accounting stock issue employee require instead transaction account fairvaluebase method sfas effective financial statement issue interim period begin june currently company disclose pro forma net income relate pro forma income share information accordance sfas accounting stockbase compensation sfas accounting stockbase compensation cost transition disclosure company evaluate impact statement material impact result operation december fasb issue fsp application sfas accounting income taxis tax deduction qualified production activity provide american job creation act effect adoption fsp material company consolidate financial statement income taxis december fasb issue fas exchange nonmonetary asset provision statement effective nonmonetary asset exchange occur fiscal period begin june provision statement apply prospectively eliminate exception fair value measurement nonmonetary exchange similar productive asset paragraph apb opinion accounting nonmonetary transaction replace exception exchange commercial substance adoption accounting pronouncement expect material effect consolidated financial statement november fasb issue sfas inventory cost amendment arb chapter standard require abnormal amount idle facility relate expense recognize current period charge require allocation fix production overhead cost conversion base normal capacity production facility sfas effective inventory cost incur fiscal year begin june company evaluate impact statement financial position result operation table content bristolmyer squibb company note consolidated financial statement continue note accounting policy continue june fasb issue fsp accounting disclosure requirement relate medicare prescription drug improvement modernization act medicare act medicare act introduce prescription drug benefit medicare federal subsidy sponsor retiree health care benefit plan provide benefit actuarially equivalent medicare fsp require effect new law account sfas employer account postretirement benefit pension company adopt fsp quarter retroactive january reduction net periodic benefit cost benefit million base remeasurement accumulate postretirement benefit obligation january effect adoption fsp material company consolidate financial statement item financial statementsnote pension postretirement benefit plan march emerge issue task force eitf reach consensus issue participate security twoclass method fas require use twoclass method compute earning share enterprise participate security multiple class common stock consensus effective fiscal period begin march adoption eitf affect company consolidate financial statement december fasb revise fin consolidation variable interest entity fin require variable interest entity consolidated company company subject majority risk loss variable interest entitys activity entitle receive majority entitys residual return fin require disclosure variable interest entity company require consolidate significant variable interest consolidation requirement fin revise apply immediately variable interest entity create january exist entity fiscal year interim period end march certain disclosure requirement apply financial statement issue january regardless variable interest entity establish accounting pronouncement material effect consolidated financial statement note alliance investment sanofiaventis company agreement sanofiaventis sanofi codevelopment cocommercialization avaproavalide irbesartan angiotensin receptor antagonist indicate treatment hypertension plavix clopidogrel platelet inhibitor worldwide alliance operate framework geographic territory america principally united states canada puerto rico latin american countries australia europe asia accordingly territory partnership form manage central expense market research development royalty supply finish product individual country general country level agreement copromote partnership form party sell brand comarket party operate sell brand independently place agreement expire later respect plavix respect avaproavalide americas australia europe asia expiration patent exclusivity right applicable territory company act operating partner territory cover americas australia own majority control interest territory sanofis ownership interest territory company consolidate country partnership result territory record sanofis share result minority interest net taxis million million million company record sale territory comarkete country germany italy spain greece million million million sanofi act operating partner territory cover europe asia own majority financial control interest territory company ownership interest territory company account investment partnership entity territory equity method record share result equity net income affiliate consolidate statement earning company share net income partnership entity tax million million million table content bristolmyer squibb company note consolidated financial statement continue note alliance investment continue company sanofi form alliance copromotion irbesartan company contribute irbesartan distribution right united states sanofi pay company total million company account transaction sale interest license defer amortize million income expect useful life license approximately year company recognize income million million million respectively unamortize portion defer income record liability section consolidate balance sheet million million december respectively otsuka company worldwide commercialization agreement otsuka pharmaceutical ltd otsuka codevelop copromote abilify aripiprazole treatment schizophrenia relate psychotic disorder japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt company begin copromote product otsuka puerto rico november june company receive marketing approval european commission product currently copromote otsuka united kingdom germany copromote france spain company records alliance revenue contractual share net sale copromotion country exclude united kingdom record expense relate product alliance revenue record company net sale base otsukas net sale copromotion country company recognize alliance revenue abilify ship risk reward ownership transfer otsukas customer company record net sale relate cost product sell company exclusive right sell abilify number country europe america asia countries sale commence company record net sale relate cost product sell term agreement company purchase product otsuka perform finish manufacture sale company customer agreement expire november puerto rico countries european union company exclusive right sell abilify agreement expire tenth anniversary commercial sale country company exclusive right sell abilify agreement expire later tenth anniversary commercial sale country expiration applicable patent country company record revenue abilify million million million total milestone payment otsuka agreement december million million expense acquire inprocess research development remain million capitalize intangible asset amortize cost product sell remain life agreement range year include million capitalize payment million payment july attainment marketing approval european union company amortize cost product sell million million million unamortized capitalize payment balance million million december respectively imclone company commercialization agreement expire september imclone biopharmaceutical company focus develop targeted cancer treatment codevelopment copromotion erbitux united states february food drug administration fda approve biologics license application bla erbitux use combination irinotecan treatment patient epidermal growth factor receptor egfrexpresse metastatic colorectal cancer refractory irinotecanbase chemotherapy use single agent treatment patient egfrexpresse metastatic colorectal cancer intolerant irinotecanbase chemotherapy accordance term agreement company pay imclone million million pay march million pay march company pay million march milestone payment initial approval erbitux additional million payable fda approval use treat additional tumor type agreement imclone receive distribution fee base flat rate product revenue north america addition company codevelopment copromotion right canada japan extent product commercialize country table content bristolmyers squibb company note consolidated financial statement continue note alliance investment continue respect million milestone payment company pay imclone million expense quarter acquire inprocess research development million record additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone company account million approval milestone pay march license acquisition amortize payment cost product sell expect useful life license approximately fourteen year amortization expense million unamortized portion approval payment record intangible net million december company account investment imclone equity method record share result equity net income affiliate consolidate statement earning company record pretax charge million temporary decline market value imclone base decline value imclone share company record investment imclone common stock december million million respectively represent approximately imclone share outstanding respectively share basis carry value imclone investment closing market price imclone share december respectively compare respectively december company determine equity share imclone net income loss eliminate imclone result milestone revenue imclone recognize preapproval milestone payment record company additional equity investment share imclone result operation company record net income million net loss million million respectively company record net sale erbitux million merck april company enter collaboration agreement merck inc merck worldwide codevelopment copromotion muraglitazar company dual ppar peroxisome proliferator activate receptor agonist currently phase iii clinical development use treat type diabetes december company submit new drug application nda fda regulatory approval murgalitazar term agreement company receive million upfront payment entitle receive additional million milestone payment december subsequently receive january company entitle receive million additional payment achievement certain regulatory milestone company merck jointly develop clinical marketing strategy muraglitazar share equally future development commercialization cost copromote product physicians global basis merck receive payment base net sale level upfront payment million receive defer amortized income expect remain useful life agreement approximately sixteen year company recognize million payment income million milestone payment defer record receivable december amortize income begin january remain useful life agreement addition company record merck share codevelopment cost reduction research development expense mercks share copromotion cost reduction advertising product promotion expense summary financial information follow summarize financial information company equity investment imclone joint venture sanofi europe asia unaudite dollar million revenue gross profit net income current asset noncurrent asset current liability noncurrent liability table content bristolmyers squibb company note consolidated financial statement continue note restructure item activity company record pretax restructuring charge million relate downsize streamline worldwide operation rationalization worldwide manufacturing operation charge million relate primarily employee termination benefit approximately employee include manufacture administrative sale personnel europe north america asia latin america exit cost million relate primarily lease termination cost item million relate primarily relocation expense result consolidation research facility charge partially offset adjustment change estimate prior period reserve million principally reduce separation cost million gain sale research facility previously write restructure company expect complete restructuring activity follow table present detail provision restructure item operating segment type company allocate restructuring charge business segment employee employee termination exit termination benefit cost item total dollar millions pharmaceutical healthcare reduction reserve change estimate gain sale research property provision restructure item addition company record million asset impairment accelerate depreciation relate rationalization manufacturing operation primarily cost product sell million research development relate upfront payment licensing agreement allocate business segment activity company record pretax restructuring charge million relate downsize streamline worldwide operation rationalization worldwide manufacturing operation charge million relate primarily termination benefit approximately employee include manufacture administrative sale personnel europe north america asia latin america item million relate primarily relocation expense result consolidation research facility charge partially offset adjustment change estimate prior period reserve million principally higher anticipate proceed disposal asset reduce separation cost company expect complete restructuring activity follow table present detail provision restructure item operating segment type company allocate restructuring charge business segment employee employee termination exit termination benefit cost item total dollar millions pharmaceuticals healthcare subtotal reduction reserve change estimate provision restructure item addition company record million asset impairment accelerate depreciation relate rationalization manufacturing operation cost product sell million research development relate upfront payment licensing agreement allocate business segment table content bristolmyers squibb company note consolidated financial statement continue note restructure item continue activity company record pretax restructuring charge million relate reduction elimination nonstrategic research effort consolidation research facility workforce reduction downsize streamline worldwide operation charge million relate employee termination benefit approximately employee include research manufacturing sale administrative personnel million represent asset writedown include million impairment charge company investment deltagen million exit cost closure facility relate expense charge offset adjustment prior period restructure reserve million million lower expect separation cost million higher anticipate proceed disposal asset previously write restructure million project cancel addition million adjustment cost product sell reflect reversal inventory reserve associate cancel project company complete restructuring activity follow table present detail provision restructure item operating segment type company allocate restructuring charge business segment employee employee termination exit termination benefit cost item total dollar million pharmaceutical nutritional healthcare corporateother subtotal reduction reserve change estimate provision restructure item addition million accelerate depreciation relate plan shutdown research facility united states include research development expense million inventory writeoff associate project include cost product sell quarter company record pretax restructure charge million severance exit cost associate consolidation research development effort closure lease facility result action impairment assessment perform long live asset site accordance sfas company conclude million asset recoverable remain useful life asset mainly laboratory equipment leasehold improvement alternate use residual value accelerate year month reflect date abandonment facility fourth quarter table content bristolmyer squibb company note consolidated financial statement continue note restructure item continue rollforward restructuring charge spend liability associate prior current action follow employee termination exit cost liability liability total dollar million balance december charge spend change estimate balance december charge spend change estimate balance december charge spend change estimate balance december liability include accrue expense consolidate balance sheet note acquisition divestiture february company complete divestiture adult nutritional business novartis novartis million include million contingent achievement contractual requirement satisfy million upfront payment supply agreement company record pretax gain million million net tax include million contingent payment million reduction company goodwill associated mead johnson product line adult nutritional product record sale million april company complete acquisition acordis speciality fibre acordis headquartered united kingdom supplies material convatec wound therapeutic line acquisition expect strengthen company leadership position wound therapy company purchase stock acordis million incur million acquisition cost connection transaction additional million payment contingent achievement future sale volume purchase price acquisition allocate tangible identifiable intangible asset acquire liability assume base estimate fair value acquisition date million million allocate inprocess research development represent estimate fair value acquire inprocess project consist primarily medicel wound therapeutic product reach technological feasibility alternative future use expense estimate fair value project determine employment discount cash flow model million assign identifiable intangible asset predominantly patent excess purchase price estimate fair value net asset acquire approximately million record goodwill acquisition account purchase method accordingly result operation include accompany consolidated financial statement date acquisition company complete sale brand product moisturel duricef result pretax gain million note discontinue operation december commit plan sell otn enter definitive sale agreement equity partner llc otn lead specialty distributor pharmaceutical product officebase oncologist united states report distinct operating segment transaction expect complete half sale price equal million plus sale price adjustment sale price adjustment base excess current asset current table content bristolmyer squibb company note consolidated financial statement continue note discontinued operation continue liability work capital closing date sale price shall increase decrease work capital exceed million closing date sale result pretax gain approximately million subject sale price adjustment postclosing matter gain sale otn recognize closing date follow amount related otn business segregate continue operation report discontinued operation reflect cost certain service provide otn company cost allocate company otn service include legal counsel insurance external audit fee payroll process certain human resource service information technology system support year end december dollar million net sale cost product sell gross profit total operating expense earning income taxis provision income taxis net earning discontinue operation net earning discontinue operation include million statement earning primarily relate reduction tax contingency reserve relate spinoff zimmer holdings inc follow summary asset liability discontinue operation expect sell amount present derived historical financial information otn adjusted exclude cash intercompany receivables payable otn company exclude divestiture addition goodwill relate otn december million exclude follow summary net asset dispose consider determine gain sale date transaction consummate dollar million asset receivables net current asset total current asset property plant equipment noncurrent asset total asset liability account payable accrue expense total liability net asset sell account payable balance primarily include payable mckesson corporation mckesson december usually pay day month good ship precede month result timing account payable balance otn net liability balance december consolidate statement cash flow include otn business period present company use centralized approach cash management financing operation accordingly debt allocate business cash inflow operate investing activity discontinue operation million million year end december respectively cash outflow million year end december table content bristolmyers squibb company note consolidated financial statement continue note earning share numerator basic earning share net earning available common stockholder numerator diluted earning share net earning available common stockholder interest expense add assume conversion convertible debt common share denominator basic earning share weight average number common share outstanding period denominator diluted earning share weight average share outstanding adjusted effect dilutive stock option computation basic earning common share dilute earning common share follow year end december dollar million share amount earning continue operation discontinue operation net earning net gain disposal net earning basic average common share outstanding earning continue operation discontinue operation net earning net gain disposal net earning dilute average common share outstanding conversion convertible debt bond incremental share outstanding assume exercise dilutive stock option earning continue operation discontinue operation net earning net gain disposal net earning weightedaverage share issuable exercise stock option include diluted earning share calculation dilutive million million million net earning include interest expense million million respectively add assume conversion convertible debt common share table content bristolmyer squibb company note consolidated financial statement continue note expense net component expense net year end december dollar million interest expense interest income foreign exchange transaction loss net net expense net interest expense reduce net interest swap gain million million million respectively interest income relate primarily cash cash equivalent investment marketable security income include income thirdparty contract manufacture royalty income gain loss disposal property plant equipment note income taxis component earning loss continue operation minority interest income taxis year end december dollar million nonus amount categorize base location tax authority provisionbenefit income taxis attributable continue operation consist year end december dollar millions current nonus defer nonus table content bristolmyer squibb company note consolidated financial statement continue note income taxis continue company provision income taxis different compute apply statutory federal income tax rate earning continue operation minority interest income taxis result follow earning minority interest income taxis dollar million earning continue operation minority interest income tax statutory rate effect operation ireland puerto rico switzerland state local taxis net valuation allowance change estimate contingent tax matter nondeductible reserve anticipate dividend repatriation ajca federal foreign valuation allowance foreign effective income tax rate earning continue operation minority interest income taxis compare high effective tax rate attributable primarily million charge estimate defer taxis take fourth quarter anticipation repatriate approximately billion special dividend company nonus subsidiary pursuant ajca increase estimate contingent tax matter compare charge relate establishment valuation allowance certain charitable contribution carryforward partially offset favorable resolution certain tax refund claim increase foreign tax credit effect certain litigation reserve nondeductible increase effective tax rate effective tax rate primarily decrease effective tax rate benefit operation ireland puerto rico switzerland treatment provision certain litigation reserve nondeductible increase estimate contingent tax matter compare component current noncurrent defer income tax asset liability december dollar millions acquire inprocess research development intercompany profit inventory item foreign tax credit carryforward defer income alternative minimum tax research development credit carryforward charitable contribution carryforward state tax net operating loss carryforward foreign net operating loss credit carryforward postretirement pension benefit depreciation defer foreign currency gainloss anticipate dividend repatriation ajca net valuation allowance defer tax asset net recognize deferred income taxis current deferred income taxis noncurrent foreign income taxis payable liability noncurrent total table content bristolmyer squibb company note consolidated financial statement continue note income taxis continue valuation allowance million december relate million foreign state net defer tax asset million foreign state net operating loss tax credit carryforward million charitable contribution carryforward company currently believe likely realize income taxis pay year million million million respectively current tax benefit realize exercise stock option charge capital excess par value stock amount million million million respectively december company approximately billion undistributed earning foreign subsidiary company accrue provision million estimate deferred taxis fourth quarter anticipation repatriate approximately billion earning pursuant ajca company estimate tax cost relate repatriation revise result additional guidance clarify language issue congress andor department treasury change companys factual assumption occur taxis provide balance undistribute earning approximately billion company invest expect invest undistributed earning permanently offshore future earning repatriate united states company determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide company settle federal income tax return internal revenue service irs company establish liability possible assessment tax authority result know tax exposure include limited transfer price certain tax credit state foreign tax matter amount represent reasonable provision taxis ultimately expect pay need adjusted time information know december certain tax contingency liability establish company reasonably estimate possible contingency possible contingency material effect change estimate related contingent tax matter include rate reconciliation year end december company recognize income tax benefit million settlement certain prior year tax matter determination company expect settlement tax litigation company reorganize structure ownership nonus subsidiary principal purpose reorganization facilitate company ability efficiently deploy financial resource outside united states company believe reorganization transaction generally taxfree inside outside united states possible tax authority particular jurisdiction assert tax liability arise reorganization transaction operation reorganize subsidiary reasonably possible predict tax authority assert tax liability reasonably estimate possible loss range loss respect assert tax liability company vigorously challenge assertion believe prevail assurance result company prevail final non appealable determination possible impact material note receivables major category receivables follow december dollar million trade receivables miscellaneous receivable allowance receivables net table content bristolmyer squibb company note consolidated financial statement continue note inventory major category inventory follow december dollar million finish good work process raw packaging material inventory net note consignment company experience substantial buildup wholesaler inventory pharmaceutical business result sale incentive offer company wholesaler october company determine require restate sale earning correct error time revenue recognition certain sale large wholesaler pharmaceuticals business company determine sale account consignment model describe note accounting policiesrevenue recognition base relationship nature incentive offer wholesaler inventory hold wholesaler consignment model transaction result defer revenue million december defer revenue december inventory account consignment model fully work company recognize approximately million million million defer revenue net sale respectively net rebate return adjustment note property plant equipment major category property plant equipment follow december dollar million land building machinery equipment fixture construction progress accumulate depreciation property plant equipment net capitalize interest include category property plant equipment show company capitalize interest million million million year end december respectively note goodwill change carry goodwill year end december follow pharmaceutical nutritional healthcare discontinue segment segment segment operation total dollar million balance december purchase accounting adjustment reduction sale adult nutritional business purchase price allocation adjustment balance december table content bristolmyers squibb company note consolidated financial statement continue note intangible asset intangible asset major asset class follow december dollar million patentstrademark license technology accumulate amortization net carrying amortization expense intangible asset majority include cost product sell year end december million million million respectively expect amortization expense relate current net carrying intangible asset follow year end december dollar million later year note shortterm borrowing longterm debt include shortterm borrowing amount foreign bank million million current installment longterm debt million million december respectively shortterm borrowing primarily consist commercial paper million december average interest rate commercial paper outstanding december proceed commercial paper issuance general corporate purpose average interest rate international shortterm borrowing current installment longterm debt outstanding december respectively compare respectively december december company replace prior billion revolving credit facility new billion year revolve credit facility syndicate lender extendable anniversary date consent lender facility contain financial covenant ratio consolidated debt consolidated capital exceed company compliance covenant inception new facility borrowing outstanding revolve credit facility december company unused shortterm line credit foreign bank million million december respectively table content bristolmyers squibb company note consolidated financial statement continue note shortterm borrowing longterm debt continue component longterm debt follow december dollar million note note float rate convertible debenture note note debenture debenture debenture yen note yen note euro interest yen principal term loan industrial revenue bond yen note yen note variable rate industrial revenue bond company outstanding billion convertible debenture pay interest quarterly annual rate equal month libor reset quarterly minus yield zero final maturity september debenture callable par time september issuer holder redeem debenture par september fundamental change ownership company occur bond initial conversion price conversion rate share adjustable depend average closing price applicable period maximum conversion rate share company enter fixed float interest rate swap billion longterm debt cash payment interest million million million respectively payment period later total year dollar million longterm debt obligation include shortterm borrowing company consolidated balance sheet balance represent outstanding nominal long term debt value company convertible debenture include payment contain feature describe december company provide financial guarantee form standby letter credit performance bond majority standby letter credit insurance company support thirdparty liability program performance bond relate sale company product foreign ministry health middle east company believe significant majority guarantee expire funded amount obligation present follow table expiration period total year year dollar million standby letter credit performance bond guarantee total commercial commitment table content bristolmyers squibb company note consolidated financial statement continue note stockholder equity change common share treasury stock capital excess par value stock restrict stock capital excess common share treasury cost treasury par value restrict issue share stock stock stock dollar share million balance december issue pursuant stock plan option amortization restrict stock lapse forfeiture restrict stock purchase balance december issue pursuant stock plan option amortization restrict stock lapse forfeiture restrict stock balance december issue pursuant stock plan option amortization restrict stock lapse forfeiture restrict stock balance december share company prefer stock convertible share common stock callable company option reduction number issue share prefer stock conversion share common stock dividend declare common share accumulate balance relate component comprehensive income loss follow defer minimum accumulate foreign loss pension available currency effective liability sale comprehensive translation hedge adjustment security incomeloss dollar million balance december comprehensive income loss balance december comprehensive income loss balance december comprehensive income loss balance december stock compensation plan companys stock incentive plan executive officer key employee grant option purchase company common stock market price date option grant option generally exercisable installment year fourth anniversary grant date maximum term year additionally plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price term stock incentive plan authorize share include outstanding share year number share tender prior year pay purchase price option number share previously utilize satisfy withholding tax obligation exercise share available grant prior year grant year share cancel forfeit expire available future grant stock incentive plan provide grant common stock key employee subject restriction continuous employment restriction generally expire fiveyear period date grant compensation expense table content bristolmyer squibb company note consolidated financial statement continue note stockholder equity continue recognize restrict period december million million share restrict stock outstanding plan respectively million share restrict stock grant fair value stock incentive plan incorporate company longterm performance awards award deliver form target number performance share threeyear cycle award base eps growth sale growth ultimate payout modify company total stockholder return versus company proxy peer group threshold target meet performance period payment longterm performance award plan maximum performance measure result maximum payout target december million million performance share outstanding plan respectively million performance share grant fair value teamshare stock option plan fulltime employee exclude key executive grant option purchase company common stock market price date option grant company authorize million share issuance plan individual grant generally exercisable evenly fourth fifth anniversary grant date maximum term year option million share exercise plan december fair value option grant estimate common share common share common share respectively date grant blackschole optionprice model follow assumption dividend yield volatility riskfree interest rate expect life year stock option transaction share common stock weight average available issue exercise option price award plan share share million balance december authorize grant exercise lapsed balance december authorize grant exercise lapsed balance december authorize grant exercise lapsed balance december table content bristolmyers squibb company note consolidated financial statement continue note stockholder equity continue follow table summarize information concern company stock compensation plan currently outstanding exercisable option number security remain available future issuance number equity security weight compensation issue average plan exercise exclude exercise price security outstanding outstanding reflect option option column plan category right right share share million million equity compensation plan approve security holder equity compensation plan approve security holder option outstanding option exercisable weighted average weighted weight remain average average number contractual exercise number exercise range exercise price outstanding life price exercisable price share share million year millions december million share common stock reserve issuance pursuant stock plan option conversion prefer stock option relate discontinued operation include amount material note financial instrument company expose market risk change currency exchange rate interest rate accordingly company utilize foreign exchange option forward contract offset effect exchange rate fluctuation anticipate foreign currency transaction primarily intercompany inventory purchase expect occur year company exposure net foreign currency denominate asset liability approximate million million december respectively primarily europe japan mexico canada foreign exchange option contract forward contract hedge anticipate transaction company primary foreign currency exposure relation dollar euro canadian dollar australian dollar japanese yen notional amount companys foreign exchange derivative contract december million million respectively derivative majority qualify hedge future anticipate cash flow effective portion change fair value temporarily defer comprehensive income oci recognize earning hedge item affect earning sfas require company perform periodic assessment hedge effectiveness assessment determine derivative designate qualifying hedge continue highly effective offset change cash flow hedge item ineffective portion fair value long defer oci include current period earning year end december company recognize loss ineffective contract million fair value option forward contract liabilitie million million december respectively record asset accrue liability december fair value foreign exchange contract base yearend currency rate black schole model case option contract addition foreign exchange hedge contract note company use foreign exchange forward contract hedge foreign currency denominate monetary asset liability primary objective foreign exchange forward contract protect dollar value foreign currency denominate monetary asset liability effect table content bristolmyers squibb company note consolidated financial statement continue note financial instrument continue volatility foreign exchange occur prior receipt settlement dollar foreign currency denominate monetary asset liability primarily denominate japanese yen euro forward contract designate hedge mark market incomeexpense notional fair value foreign exchange forward contract december million million respectively company use derivative instrument interest rate risk management policy derivative instrument comprise principally fix float rate interest rate swap subject fairvalue hedge accounting treatment company enter fix float interest rate swap contract financial institution notional amount swap billion billion december respectively accordance sfas accounting derivative instrument hedging activity company recognize net reduction interest expense million million million respectively reflect benefit lower float rate obtain swap compare fix rate underlie debt swap contract underlie debt hedge record fair value result increase noncurrent asset million shortterm liabilitie million longterm debt million increase noncurrent asset long term debt million december respectively swap contract generally hold maturity company use derivative financial instrument speculative purpose company reclassify deferred loss million million million respectively comprehensive income earning majority classify cost product sell carry company financial instrument include cash cash equivalent marketable security account receivable account payable approximate fair value december longterm debt note difference fair value carry value material note segment information company organize pharmaceutical company relate healthcare business reportable segmentspharmaceutical nutritional healthcare pharmaceutical segment comprise global pharmaceutical international exclude japan consumer medicine business nutritional segment consist mead johnson primarily infant formula business healthcare segment consist convatec medical imaging consumer medicine united states japan business company product sell principally wholesale retail trade nationally internationally certain product sell drug manufacturer hospital clinic government agency medical profession wholesaler account approximately respectively company total net sale sale wholesaler account respectively company total net sale wholesaler account approximately respectively company total net sale sale concentrate pharmaceutical segment business segment earning minority net sale interest income taxis yearend asset dollar million pharmaceutical nutritional healthcare total segment corporateother total table content bristolmyer squibb company note consolidated financial statement continue note segment information continue corporateother consist principally interest income interest expense certain administrative expense allocation business segment certain corporate program corporateother include gain sale businessesproduct line million million respectively accelerate depreciation million termination benefit exit cost million million million respectively asset writedown impairment charge million million respectively upfront milestone payment license agreement million million respectively litigation charge net million million million respectively acquire inprocess research development charge million include million asset impairment charge imclone pharmaceutical segment includes accelerate depreciation million certain manufacturing facility north america expect close relocation million retention million pharmaceutical include litigation settlement income million upfront payment licensing agreement million million accelerate depreciation asset manufacturing facility north america expect closed end million charge asset impairment million charge relocation expense million charge retention bonus benefit additionally pharmaceutical segment include charge acquire inprocess research development million corporateother asset include cash cash equivalent marketable security goodwill asset otn hold available sale certain asset capital expenditure depreciation dollar million pharmaceutical nutritional healthcare total segment corporateother total geographic area net sale yearend asset dollar millions united states europe middle east africa western hemisphere pacific total table content bristolmyer squibb company note consolidated financial statement continue note lease minimum rental commitment noncancelable operating lease primarily real estate motor vehicle effect december year end december dollar million later year total minimum payment total minimum sublease rental net minimum rental commitment operate lease rental expense net sublease rental income million million million million million million note pension postretirement benefit plan company certain subsidiary define benefit pension plan define contribution plan regular fulltime employee principal pension plan bristolmyers squibb retirement income plan fund policy contribute amount provide current service fund past service liability plan benefit base primarily year credit service participant compensation plan asset consist principally equity fix income security company provide comprehensive medical group life benefit substantially retiree elect participate comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement original retire company life insurance plan noncontributory plan asset consist principally equity fixedincome security similar plan exist employee certain country outside united states cost company defer benefit postretirement benefit plan include follow component pension benefit benefit dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset net amortization deferral net periodic benefit cost curtailment settlement total net periodic benefit cost company recognize impact medicare prescription drug improvement modernization act accordance fsp record million reduction net periodic benefit cost change benefit obligation plan asset december company define benefit postretirement benefit plans table content bristolmyers squibb company note consolidated financial statement continue note pension postretirement benefit plan continue pension benefit benefit dollar million benefit obligation begin year service costbenefit earn year interest cost project benefit obligation plan participant contribution curtailment settlement actuarial gainloss plan amendment benefit pay exchange rate loss benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution plan participant contribution settlement transfer inout benefit pay exchange rate gain fair value plan asset end year fund status unamortized net obligation adoption unrecognize prior service cost unrecognized net actuarial loss net recognize amount recognize balance sheet consist prepay benefit cost accrue benefit cost intangible asset accumulate comprehensive income net recognize plan underfunde accrue benefit obligation exceed accrue benefit liability december additional minimum liability establish increase accrue benefit liability value underfunde accrue benefit obligation liability total million million december respectively unfunded benefit equalization plan international plan additional minimum liability offset intangible asset million million charge comprehensive income include stockholder equity million million december respectively accumulate benefit obligation define benefit pension plan million million december respectively information pension plan accumulate benefit obligation excess plan asset december dollar millions project benefit obligation accumulate benefit obligation fair value plan asset table content bristolmyer squibb company note consolidated financial statement continue note pension postretirement benefit plan continue attributable primarily unfunded benefit equalization plan plan international market unfunde benefit equalization plan provide pension benefit employee compensation irs limit fund taxadvantage manner additional information pertaining company pension postretirement plan pension benefit benefit dollar million increase minimum liability include impact foreign currency fluctuation include comprehensive income weightedaverage assumption determine benefit obligation december pension benefit benefit discount rate rate compensation increase weightedaverage actuarial assumption determine net periodic benefit cost year end december pension benefit benefit discount rate expect longterm return plan asset rate compensation increase december company expect longterm rate return pension plan asset target asset allocation public equity international private equity fix income approximate apply expect return public equity private equity fix income target allocation actual historical return relevant annualize return period end december year year year pension plan asset represent approximately total company pension plan asset december disclose total company expect return asset pension plan impact international pension plan typically employ aggressive asset allocation expect return disclose benefit relevant asset invest manner pension plan asset international plan asset assume health care cost trend rate december health care cost trend rate assume year rate cost trend rate assume decline ultimate trend rate year rate reach ultimate trend rate table content bristolmyer squibb company note consolidated financial statement continue note pension postretirement benefit plan continue assume health care cost trend rate effect amount report health care plan onepercentagepoint change assume health care cost trend rate follow effect percentage percentage point increase point decrease effect total service interest cost effect postretirement benefit obligation company asset allocation pension postretirement benefit december pension benefit benefit public equity security debt security include cash private equity total company investment strategy emphasize equity order achieve high expect return long run low expense low require cash contribution pension plan target asset allocation public equity international private equity fix income maintain cash flow cash contribution benefit payment rebalance target necessary investment diversify major asset category equity passively manage investment actively manage investment strategy international pension plan typically similar asset allocation usually conservative bristolmyer squibb company common stock represent plan asset december asset postretirement benefit commingle pension plan asset investment strategy identical describe pension plan contribution minimum contribution require company plan cash contribution pension plan contribution pension plan company taxdeductible contribution account retiree medical benefit equal portion pension normal cost contribution international pension plan expect million range estimate future benefit payment follow benefit payment reflect expect future service appropriate expect pay benefit pension medicare benefit gross subsidy net dollar million year table content bristolmyers squibb company note consolidated financial statement continue note pension postretirement benefit plan continue saving plan principal define contribution plan bristolmyer squibb saving investment program company contribution base employee contribution level company match company contribution plan million million million note legal proceeding contingency legal proceeding contingency lawsuit claim proceeding investigation pende company certain subsidiary accordance sfas accounting contingency company record accrual contingency probable liability incur loss reasonably estimate matter involve antitrust security patent infringement employee retirement income security act amend erisa pricing sale marketing practice environmental health safety matter product liability insurance coverage significant matter describe assurance increase scope matter future lawsuit claim proceeding investigation material management continue believe previously disclose year aggregate impact current reserve legal matter affect company reasonably likely material company result operation cash flow material financial condition liquidity company decision obtain insurance coverage dependent market condition include cost availability exist time decision result external factor availability insurance restrictive cost increase significantly company evaluate risk determine cost obtain insurance outweighs benefit coverage protection loss selfinsure product liability effective july company continue evaluate risk benefit determine insurance need future plavix litigation united states company territory partnership alliance sanofi plaintiff pende patent infringement lawsuit institute district court southern district new york entitle sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership apotex inc apotex corp shs sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership reddys laboratories ltd reddys laboratories inc shs sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership teva pharmaceuticals usa inc teva pharmaceuticals industries ltd teva pharmaceuticals industries ltd dismiss case proceeding involve plavix institute outside united states significant proceeding pende canada describe suit file march september respectively base patent composition matter patent disclose claim thing hydrogen sulfate salt clopidogrel market plavix suit base patent disclose claim thing use clopidogrel prevent secondary ischemic event plaintiff later withdraw patent lawsuit plaintiff infringement position base defendant file abbreviate new drug application anda fda seek approval sell generic clopidogrel bisulfate prior expiration composition matter patent defendant respond allege patent invalid andor unenforceable apotex add antitrust counterclaim case consolidate discovery fact discovery close october expert discovery complete november trial occur early second quarter occur later discovery commence action company territory partnership alliance sanofi plaintiff pende patent infringement lawsuit institute district court district new jersey entitle sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership watson pharmaceuticals inc watson laboratories inc suit file october base patent disclose claim particular crystalline polymorph form hydrogen sulfate salt clopidogrel market plavix case early stage discovery begin table content bristolmyer squibb company note consolidated financial statement continue note legal proceeding contingency continue plavix currently company large product rank net sale net sale plavix approximately billion billion year end december respectively currently company expect plavix market exclusivity united states composition matter patent plavix find infringe invalid andor unenforceable district court level fda approve defendant andas sell generic clopidogrel generic competition plavix begin company exhaust appeal generic competition likely result substantial decrease sale plavix united states plaintiff intend vigorously pursue enforcement patent right plavix possible time reasonably assess outcome lawsuit company prevail lawsuit time potential generic competition plavix generic competition occur company believe unlikely occur second half possible reasonably estimate impact lawsuit company loss market exclusivity plavix subsequent development generic competition material company sale plavix result operation cash flow material financial condition liquidity canada sanofisynthelabo sanofisynthelabo canada inc institute prohibition action federal court canada apotex inc apotex minister health response notice allegation apotex direct canadian patent cover clopidogrel bisulfate apotexs notice allegation noa indicate file abbreviate new drug submission ands clopidogrel bisulfate tablet seek approval notice compliance and expiration canadian patent expire august apotexs noa allege patent invalid infringe hear hold february february decision expect april date statutory month stay impose approval apotexs and expire decision favorable apotex result generic product market canada second quarter company believe outcome canada predictive outcome light different procedural substantive rule jurisdiction sanofiaventis sanofisynthelabo canada inc institute prohibition action federal court canada novopharm limited novopharm minister health response notice allegation novopharm direct canadian patent cover clopidogrel bisulfate novopharm notice allegation noa indicate file abbreviate new drug submission ands clopidogrel bisulfate tablet seek approval notice compliance and expiration canadian patent expire august novopharm noa allege patent invalid action early stage hear date set united kingdom december aircoat limit aircoat file nullity petition court session glasgow scotland nullity petition aircoat seek revocation european patent register united kingdom european patent cover inter alia clopidogrel bisulfate active ingredient plavix aircoat specifically allege claim european patent invalid revoke ground lack novelty andor lack inventive step patent litigation tequin company kyorin pharmaceuticals ltd kyorin commence patent infringement action march teva usa teva industries united states district court southern district new york relate antibiotic gatifloxacin kyorin hold composition matter patent company sell tequin teva industry dismiss case action relate tevas file anda generic version gatifloxacin tablets certification composition matter patent expire december invalid table content bristolmyer squibb company note consolidated financial statement continue note legal proceeding contingency continue infringe filing suit place stay approval tevas generic product june court decision adverse company kyorin date erbitux october complaint file yeda research development company ltd yeda imclone aventis pharmaceuticals inc district court southern district new york action allege seek individual associate yeda name coinventor patent cover therapeutic combination egfrspecific monoclonal antibody antineoplastic agent chemotherapeutic agent use treatment cancer yeda action successful yeda position practice license practice invention result product competition erbitux occur company party action unable predict outcome stage proceeding repligen corporation repligen massachusetts institute technology mit file lawsuit united states district court district massachusetts imclone claim imclone manufacture sale erbitux infringe patent generally cover process protein production mammalian cell repligen mit seek damage base sale erbitux commence february patent expire repligen mit seek extension patent company party action unable predict outcome stage proceeding abilify august otsuka file united states patent trademark office uspto request reexamination composition matter patent cover abilify antipsychotic agent treatment schizophrenia patent number patent expire extend pende supplemental protection extension grant otsuka determined original patent application contain error description prior art reference identify wrong patent number addition otsuka take opportunity bring citation attention uspto uspto grant request reexamination reexamination proceed ongoing reexamination proceeding allow uspto consider patentability patent claim light correct patent number newly cite document uspto expect final decision reexamination month company otsuka believe invention claim patent patentable prior art expect uspto reconfirm reexamination guarantee outcome patentability patent reconfirm follow reexamination soon expect loss market exclusivity abilify subsequent development generic competition material company avalide ranbaxy laboratory limit ranbaxy serve notice file anda piv certification direct patent formulation patent expire june ranbaxys piv notice assert propose generic formulation infringe patent ranbaxys piv notice include challenge composition matter patent currently expire september company partner sanofi currently evaluate ranbaxys piv notice avapro ranbaxy serve notice file anda piv certification direct patent formulation patent expire june ranbaxys piv notice assert propose generic formulation infringe patent ranbaxys piv notice include challenge composition matter patent currently expire september company partner sanofi currently evaluate ranbaxys piv notice tequin injectable form apotex corp apotex sicor pharmaceuticals inc sicor american pharmaceutical partners inc app serve notice file abbreviate nda piv certification direct patent apotex sicor submit piv certification patent patent composition matter patent expire december patent term extension apply december patent cover specific form gatifloxacin tequin apotex sicor allege piv notice patent invalid apotex sicor app allege propose generic formulation infringe patent company currently evaluate piv notice vanlev litigation april june company chairman board chief executive officer charle heimbold chief scientific officer peter ringrose phd name defendant number class action lawsuit allege violation federal security law regulation action consolidate action district table content bristolmyer squibb company note consolidated financial statement continue note legal proceeding contingency continue court district new jersey plaintiff claim defendant disseminate materially false misleading statement andor fail disclose material information concern safety efficacy commercial viability product vanlev period november april plaintiff submit amend complaint add allegation company present chairman board chief executive officer peter dolan chairman board chief executive officer charle heimbold chief scientific officer peter ringrose phd disseminate materially false misleading statement andor fail disclose material information concern safety efficacy commercial viability vanlev period april march number relate class action make essentially allegation file district court southern district new york action transfer district court district new jersey company file motion partial judgment favor base pleading plaintiff oppose motion seek amend complaint court grant deny company motion rule plaintiff amend complaint challenge certain allege misstatement court certify separate class class relate period november april class relate period march march class certification propose class certification prejudice defendant right fully contest merit plaintiff claim plaintiff purport seek compensatory damage cost expense behalf shareholder respect class period propose class period december company defendant motion summary judgment plaintiff claim final pretrial conference matter commence december schedule complete trial date set january plaintiff move leave file amend complaint seek combine class period expand class period october march add allegation company peter dolan charles heimbold peter ringrose phd disseminate materially false misleading statement fail disclose material information concern safety efficacy commercial viability vanlev defendant oppose plaintiff motion court schedule hear oral argument motion april possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonappealable determination litigation impact material security matter period march company number current officer name defendant number security class action suit suit variously allege violation federal security law regulation connection different matter vanlev discuss sale incentive wholesaler inventory level imclone imclone product erbitux discuss allegation concern vanlev transfer district court district new jersey consolidated action pende remain action consolidate pende district court southern district new york plaintiff file consolidated class action complaint april company certain current officer allege class period october march consolidated class action complaint allege violation federal security law connection thing company investment relationship imclone imclone product erbitux certain accounting issue include issue relate wholesaler inventory sale incentive establishment reserve account certain asset sale plaintiff seek compensatory damage cost expense march district court grant company motion dismiss consolidated class action complaint dismiss case prejudice plaintiff appeal dismissal second circuit court appeal court appeal appeal pende party reach agreement principle settle action july court appeal stay appeal remand action district court district court consider settlement july district court vacate clerk judgment order consider settlement day district court enter order preliminarily approve settlement certify class settlement purpose pursuant term propose settlement claim action dismiss litigation terminate defendant receive release company pay million fund class member november fairness hear district court approve settlement judgment dismissing case prejudice settlement final company discuss recovery insurance policy reflect financial statement portion million settlement approximately million share exclude settlement pursuant request exclusion approximately million share hold plaintiff pende action discuss company establish reserve liability possible time reasonably assess final outcome lawsuit accordance gaap company determine amount represent minimum expect probable loss respect lawsuit eventual loss relate table content bristolmyer squibb company note consolidated financial statement continue note legal proceeding contingency continue lawsuit exceed reserve impact material company believe topend range loss estimate addition action file early october new york state supreme court make similar factual allegation assert variety claim include common law fraud negligent misrepresentation discovery take matter january company move dismiss complaint plaintiff file amend complaint december make similar allegation add allegation sec complaint issue august company file motion dismiss amend complaint february plaintiff opposition motion dismiss march company reply april relate action file september november december make similar factual allegation assert claim similar amend complaint new york state supreme court action file october company intend file motion dismiss relate action briefing schedule identical action file october possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonapplicable determination litigation impact material company number company current officer name defendant purport class action file october state court cook county illinois complaint make factual allegation similar settle federal class action southern district new york assert common law fraud breach fiduciary duty claim complaint purport assert claim behalf stockholder purchase company stock october hold stock march company remove action northern district illinois february plaintiffs motion remand march company opposition april plaintiff reply possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonapplicable determination litigation impact material november class action complaint file united states district court eastern district missouri company healthcare resources inc current director officer behalf purchaser stock august september class action complaint allege company participate fraudulently inflate value stock allegedly engage improper channelstuffe agreement bms file motion dismiss case january plaintiff opposition motion dismiss march company reply april private security litigation reform act discovery automatically stay pende outcome motion dismiss plaintiff file motion partially lift automatic discovery stay february company opposition motion march plaintiff reply march impact expect material begin october number company current officer director name defendant shareholder derivative suit pende district court southern district new york number company current officer director name defendant shareholder derivative suit file period march district court district new jersey july district court district new jersey order shareholder derivative lawsuit file court transfer district court southern district new york subsequently district court southern district new york order federal shareholder derivative suit consolidated plaintiff file consolidated amend verify shareholder complaint certain member board director current officer pricewaterhousecooper pwc independent register public accounting firm customary derivative suit company name defendant action nominal defendant company liable damage suit specific relief seek company consolidate amend complaint allege thing violation federal security law breach fiduciary duty certain individual defendant connection company conduct concern thing safety efficacy commercial viability vanlev discuss company sale incentive certain wholesaler inventory level wholesaler company investment relation imclone imclone product erbitux allege anticompetitive behavior connection buspar taxol lawsuit allege malpractice negligent misrepresentation negligence pwc plaintiff seek restitution rescission certain officer director compensation allege improper insider trading proceed injunctive relief fee cost expense contribution certain officer allege liability consolidated security class action pende district court southern district new york discuss contribution indemnification pwc discovery take matter december company move dismiss consolidate amend complaint motion dismiss administratively withdraw prejudice party right reinstate request similar action pende new york state court plaintiff seek equitable relief damage cost attorney fee party currently engage discussion potential settlement action previously disclose august company enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit company quarterly report form period end september consent company agree admit deny liability violate certain provision security law company agree establish million fund class shareholder distribute court supervision million fund include million civil penalty distribute certain company shareholder plan distribution establish sec table content bristolmyers squibb company note consolidated financial statement continue note legal proceeding contingency continue settlement resolve ongoing investigation sec activity certain current member company management connection wholesaler inventory issue accounting matter investigation ongoing addition investigation attorney office district new jersey concern inventory accounting matter cover company settlement sec continue company continue cooperate investigation erisa litigation december quarter company name defendant class action bring erisa district court southern district new york district new jersey action consolidated southern district new york caption bristolmyers squibb erisa litigation lap amend consolidated complaint allege class period january march serve august amend consolidated complaint bring behalf name plaintiff putative class consist participant bristolmyers squibb company saving investment program saving plan beneficiary benefit saving plan hold andor acquire company stock time class period exclude defendant heir predecessor successor assign name defendant company bristolmyer squibb company saving plan committee committee thirteen individual presently serve committee serve committee recent past charle heimbold peter dolan past present chief executive officer respectively company amend consolidated complaint generally allege defendant breach fiduciary duty erisa class period thing continue offer company stock fund company stock investment alternative saving plan continue invest company matching contribution company stock fund company stock fail disclose investment company stock allegedly imprudent saving plan purchase company stock january allege transaction prohibit erisa finally defendant heimbold dolan allege breach fiduciary duty erisa fail monitor action committee erisa claim predicate factual allegation similar raise security matter concern thing safety efficacy commercial viability vanlev company sale incentive certain wholesaler inventory level wholesaler company investment relation imclone imclone product erbitux allege anticompetitive behavior connection buspar taxol significant discovery date discovery currently stay october company defendant move dismiss amend consolidated complaint plaintiff oppose motion dismiss defendant reply motion dismiss administratively withdraw prejudice plaintiff request premotion conference intend ask court leave file second amendment complaint second quarter company establish reserve liabilitie litigation million possible time reasonably assess final outcome litigation accordance gaap company determine reserve establish represent minimum expect probable loss respect litigation eventual loss relate litigation exceed reserve impact material company believe topend range loss estimate company prevail final nonappealable determination matter impact material result operation price sale promotional practice litigation investigation company number pharmaceutical manufacturer defendant private class action action bring nevada montana pennsylvania wisconsin kentucky illinois alabama attorney general city new york new york county pende federal state court relate price certain company product federal case relate state court case remove federal court consolidate pretrial purpose caption pharmaceutical industry average wholesale price litigation mdl civ action cvpbs united states district court judge patti saris united states district court district massachusetts awp multidistrict litigation june private plaintiffs awp multidistrict litigation file amend master consolidated complaint amend master complaint amend master complaint contain set allegation company allege company pharmaceutical manufacturer report price certain drug product list drug company case effect falsely overstate average wholesale price awp publish industry compendia turn improperly inflate reimbursement pay medical provider pharmacist prescribe administer sell product consumer second allege company certain defendant pharmaceutical manufacturer conspire program call card program fix awps certain drug available consumer program amend master complaint assert claim federal rico antitrust statute state consumer protection fair trade statute table content bristolmyers squibb company note consolidated financial statement continue note legal proceeding contingency continue amend master complaint bring behalf main propose class definition subject amendment case progress december propose class summarize person entity forward pay reimburse list drug medicare private contract expressly awp pricing standard person entity forward pay reimburse portion purchase price drug cover card program base awp class divide propose subclass depend list drug question physicianadministere selfadministere sell pharmacy benefit manager specialty pharmacy brandname generic drug september plaintiffs awp multidistrict litigation move certification propose plaintiff class party brief motion relate amend propose definition main class subclass discuss motion hear court february company defendant move dismiss amend master complaint ground fail state claim applicable statute february court deny motion large court dismiss plaintiff claim failure plead cognizable rico enterprise accordingly court require company defendant answer amend master complaint court subsequently order defendant include company engage accelerate discovery respect remain allegation amend master complaint allegation relate extend discovery schedule accelerate discovery close defendant january addition company defendant obtain discovery name plaintiff nonpartie benefit consultant federal government health insurer current schedule call expert report expert deposition summary judgment briefing liability issue half case commence nevada montana pennsylvania wisconsin illinois alabama kentucky attorney general attorney general awp case case commence new york city new york counties new york city county awp case include fraud consumer protection claim similar amend master complaint certain state city county additional allegation defendant include company violate state medicaid statute thing fail provide state adequate rebate require federal law attorney general awp case montana action proceed respective state court series decision june september october affect montana attorney general case new york city county awp case proceed awp multidistrict litigation coordination private class action court decline find medicaid rebate claim preempt federal law dismiss claim relate rebate payment drug manufacturer include claim relate company insufficiently plead court allow proceed state law claim allege company misreporte awps company file answer claim remain montana attorney general complaint company join defendant motion dismiss pennsylvania attorney general action decision file february pennsylvania commonwealth court grant motion dismiss ground plaintiff fail plead complaint requisite particularity court give attorney general days replead july nevada court deny company defendant motion dismiss complaint state rico claim grant attorney general leave replead opinion base prior ruling awp multidistrict litigation court company defendant soon motion dismiss attorney general awp case company number defendant private class action make awpbase claim remand awp multidistrict litigation arizona state court individual robert swanston assert claim arizona state law behalf allege class person entity arizona pay prescription drug base awp swanston action claim generally allege defendant drug manufacturer conspire inflate awps order date august arizona court deny defendant motion dismiss stay proceeding party currently brief plaintiff motion class certification defendant paper february court swanston action order discovery matter coordinate discovery awp multidistrict litigation october company add defendant putative class action previously commence drug manufacturer federal court alabama case bring health care provider allegedly entitle federal statute section public health service act discount price prescription drug dispense poor provider local area plaintiff health care provider contend allege class provider authorize obtain discount price statute fact receive level discount entitle amend complaint company manufacturer assert claim directly federal statute table content bristolmyer squibb company note consolidated financial statement continue note legal proceeding contingency continue state law unjust enrichment accounting company join motion dismiss complaint file original manufacturer defendant court approval applicable amend complaint finally company defendant relate state court proceeding commence new york new jersey california tennessee proceeding transfer awp multidistrict litigation pretrial purpose plaintiffs california new jersey action seek remand case state court california remand motion deny new jersey remand motion remain pende case preliminary stage company unable assess outcome possible effect business profitability reasonably estimate possible loss range loss respect case company prevail final nonappealable determination litigation investigation impact material company number pharmaceutical manufacturer receive subpoenas document request government agency seek record relate pricing sale marketing practice good price report drug cover medicare andor medicaid request record come attorney office district massachusetts eastern district pennsylvania northern district texas civil division department justice offices inspector general department health human service office personnel management conjunction civil division department justice state addition request information come house committee energy commerce senate finance committee connection investigation committee currently conduct medicaid good price issue previously disclose mid company initiate internal review certain sale marketing practice focus practice comply applicable antikickback law analyze practice respect compliance good price reporting rebate requirement medicaid program certain governmental programs reference medicaid rebate program applicable fda requirement company meet representative attorney office district massachusetts discuss review receive related subpoena attorney office company internal review expect continue resolution pende governmental investigation relate matter company produce document actively cooperate investigation result assertion civil andor criminal claim second quarter company increase reserve liabilitie relation pharmaceutical pricing sale marketing practice describe section million bring total reserve liability matter million possible time reasonably assess final outcome matter accordance gaap company determine represent minimum expect probable loss respect matter loss include imposition fine penalty administrative remedy andor liability additional rebate amount eventual loss relate matter exceed reserve impact material company believe topend range loss estimate company prevail final nonappealable determination litigation investigation impact material previously disclose company undertake analysis method process calculate price report governmental rebate pricing program relate pharmaceutical business analysis complete early base analysis company identify need revision methodology process calculate report pricing relate rebate amount expect implement revise methodology process begin report federal government agency primary responsibility rebate price reporting obligation center medicare medicaid services cms quarter addition revise methodology process company recalculate good price average manufacturer price require report company federal medicaid rebate agreement certain state agreement correspond revise rebate liability amount program threeyear period quarter base result company analysis time company record additional liability equal estimate additional rebate liability result propose revision material completion analysis early company finally determine estimate rebate liability program threeyear period actually rebate pay company period accordingly fourth quarter company reverse additional rebate liability record quarter record additional reduction rebate liability estimate overpayment company propose revision update estimate submit review cms company anticipate submission cms likely review department justice doj conjunction previously disclose subpoena receive company doj relate thing good price report drug cover medicaid discuss detail agency position table content bristolmyers squibb company note consolidated financial statement continue note legal proceeding contingency continue revision company methodology calculation require completion governmental review company determine recalculation liability company identify program period similar program necessary appropriate company believe base current information recalculation likely result material rebate liability uncertainty surround recoverability company estimate overpayment arise review process describe company record reserve equal estimate overpayment company remediate internal control process procedure company believe result propose revision continue strengthen internal control company receive civil investigative demand attorney general state missouri relate directtoconsumer advertising pravachol period company receive write confirmation attorney general july concluding investigation action take company company receive notice putative class action lawsuit involve issue relate directtoconsumer advertising file february circuit court jackson county missouri kansas city caption richard summers bristolmyers squibb company company serve complaint march remove action federal court action remand state court impact expect material company number pharmaceutical manufacturer name defendant action file california state superior court oakland james clayworth bristolmyers squibb company allege defendant conspire fix price pharmaceutical prevent importation foreign drug united states assert claim california cartwright act unfair competition law plaintiff seek treble damage damage sustain restitution profit obtain defendant charge artificially high price plaintiff injunction bar defendant charge plaintiff high price offer customer award reasonable attorney fee cost relief court deem proper plaintiff propound interrogatory defendant serve objection response january party process meeting confer resolve dispute defendant response objection plaintiff propound form interrogatory request admission request production document company prepare response objection discovery request november company file demurrer action plaintiff file opposition brief december company file reply brief january oral argument demurrer hold february order date february court sustain demurrer court grant plaintiff leave file second amend complaint defendant response second amend complaint file march case preliminary stage company unable assess outcome possible effect business profitability reasonably estimate possible loss range loss respect case company prevail final nonappealable determination litigation impact material product liability litigation company party product liability lawsuit involve allegation injury cause company pharmaceutical overthecounter medication majority lawsuit involve certain overthecounter medication contain phenylpropanolamine ppa company serzone stadol prescription drug addition lawsuit company face unfiled claim involve product ppa yale university publish result hemorrhagic stroke project conclude evidence suggestion ppa increase risk hemorrhagic stroke limited population november fda issue public health advisory request manufacturer ppacontaining product voluntarily cease manufacturing marketing time ppacontaining product manufacture sell company comtrex liquigel formulation naldecon november company manufacturer ppa contain product discontinue manufacture marketing ppacontaining product allow customer return unused product possession january company serve ppa lawsuit company currently defendant approximately personal injury lawsuit file behalf approximately plaintiff federal state court united states lawsuit involve multiple defendant claim plaintiff allege ppa cause hemorrhagic ischemic stroke defendant aware risk fail warn consumer fail remove ppa product plaintiff seek compensatory punitive damage federal case transfer district court western district washington phenylpropanolamine ppa product liability litigation mdl district court deny motion class certification class action lawsuit pende company litigation table content bristolmyers squibb company note consolidated financial statement continue note legal proceeding contingency continue june district court issue rule effectively limit plaintiff claim hemorrhagic ischemic stroke ruling favorable defendant include inadmissibility expert testimony case allege injury occur day ingestion ppacontaining product case involve psychosis seizure cardiac injury company expect dismiss additional case product plaintiff plaintiff allege injury occur day ingestion ppacontaining product plaintiff suffer cardiac injury psychose serzone serzone nefazodone hydrochloride antidepressant launch company canada march united states december company add black box warn serzone label warn potential risk severe hepatic event include possible liver failure need transplantation risk death month black box warning add package insert serzone number lawsuit include class action file company plaintiff allege company know know hepatic risk pose serzone failed adequately warn physician user risk seek compensatory punitive damage medical monitoring refund cost purchase serzone company announce follow evaluation commercial potential product generic entry marketplace rapidly decline brand sale decide discontinue manufacture sale product effective june present company approximately lawsuit behalf approximately plaintiff pende federal state court united states twentyseven case pende new york state court consolidated pretrial discovery addition approximately allege unfiled claim injury associate serzone august federal case transfer district court southern district west virginia serzone product liability litigation mdl discovery early stage appear case involve liver failure june district court dismiss class claim class action complaint purport class action file illinois number class action complaint file company seek certification personal injury class remain class action complaint seek certification personal injury class addition case file united states national class action file canada admit wrongdoe liability october company enter settlement agreement respect claim united states territory serzone settlement agreement embody schedule payment dependent class member develop qualify medical condition demonstrate purchase take serzone certain criterion apply settlement subject final approval district court appeal therefrom pursuant settlement agreement plaintiff class counsel file class action complaint see relief settlement class november district court conditionally certify temporary settlement class preliminarily approve settlement optout period end april fairness hearing schedule june pursuant term propose settlement claim dismiss litigation terminate defendant receive release company commit pay million fund class member class counsel right petition court award reasonable attorney fee expense fee pay company reduce money pay class member settlement company terminate settlement base number claim submit number purport class member opt participate settlement instead pursue individual claim second quarter company establish reserve liabilitie lawsuit million possible time reasonably assess final outcome lawsuit accordance gaap company determine amount represent minimum expect probable loss respect lawsuit eventual loss relate lawsuit exceed reserve impact material company believe topend range loss estimate stadol stadol approve fda unschedule opioid analgesic nasal spray february company ask fda schedule stadol schedule low potential abuse drug postmarketing report suggestive inappropriate use product october schedule drug company receive number lawsuit involve stadol late number file suit increase newly pass tort reform legislation effective january plaintiff new suit previously assert claim company allege injury company announce follow evaluation commercial potential product generic entry marketplace rapidly decline brand sale decide discontinue manufacture sale product effective june company party approximately case pende behalf total approximately plaintiff federal state court united states plaintiff claim company commit fraud fda wrongfully promote table content bristolmyer squibb company note consolidated financial statement continue note legal proceeding contingency continue stadol nonaddictive plaintiff allege company fail adequately warn addiction dependency risk associate use stadol company reach agreement principle settle lawsuit involve approximately plaintiff addition lawsuit approximately active allege unfiled claim majority case claim pende mississippi second quarter company recover insurance proceed million respect stadol case breast implant litigation company subsidiary medical engineering corporation mec certain company remain defendant number claim lawsuit allege damage personal injury type result polyurethanecovered breast implant smoothwalle breast implant manufacture mec relate company vast majority claim company direct lawsuit resolve settlement trial likewise claim potential claim company register nationwide class action settlement approve federal district court birmingham alabama revise settlement resolve revise settlement company establish accrual respect breast implant product liability litigation company believe possible loss addition amount accrue material hormone replacement therapy hrt litigation national institute health begin clinical trial involve prempro estrogen progestin premarin estrogen manufacture wyeth july jama article report prempro subject increase risk breast cancer heart attack blood clot stroke prempro phase study stop july july company serve hrt lawsuit company product involve litigation estrace estrogenonly tablet estradiol generic estrogenonly tablet delestrogen injectable estrogen ovcon oral contraceptive contain estrogen progestin product sell company january august company maintain estrace anda company currently defendant approximately lawsuit include abovementione product file behalf approximately plaintiff federal state court united states majority lawsuit involve multiple defendant company expects dismiss case product plaintiff allege thing product cause breast cancer stroke blood clot cardiac injury woman defendant aware risk fail warn consumer federal case transfer district court eastern district arkansas prempro wyeth product liability litigation mdl company vigorously defend product liability lawsuit believe majority case claim merit possible time reasonably assess final outcome company pende product liability lawsuit unfiled claim certainty management opinion ultimate disposition matter material adverse effect company financial position indicate company believe adequate selfinsurance reserve commercially available excess insurance cover potential material loss relate product liability case claim environmental proceeding follow discussion describe environmental proceeding governmental authority involve potential monetary sanction threshold prescribe specific sec rule civil action environmental claim result significant liability update ongoing matter resolution matter disclose recent public filing summary environmental remediation cost result internal audit perform company facility hopewell indicate operation site wastewater treatment plant relate discharge compliance new jersey water pollution control act implement regulation term company discharge permit company report finding new jersey department environmental protection njdep february enter settlement agreement njdep november pay penalty result audit suggest adverse impact public health company take continue corrective action address identify deficiency prevent future occurrence environmental protection agency epa investigate industrial commercial facility use refrigeration equipment contain ozonedeplete substance od enforce compliance regulation govern prevention service repair leak od requirement recently company perform voluntary corporatewide audit table content bristolmyer squibb company note consolidated financial statement continue note legal proceeding contingency continue facility puerto rico use odscontaine refrigeration equipment company submit audit report epa november identify potential violation od requirement facility currently discussion epa resolve matter addition matter cover company audit report letter epa epa previously send company wholly own subsidiary mead johnson request information compliance od requirement facility evansville indiana company respond request june epa currently process review information company provide epa determine evansville facility facility violation applicable od requirement company subject penalty andor require convert replace refrigeration equipment use non od approve substitute january njdep send company approximately company information request letter relate site north brunswick township waste material squibb son squibb wholly own subsidiary company disposed fill material contain industrial waste heavy metal excess residential standard discover fall expansion project north brunswick township high school number neighbor residential property adjacent public park area school board township current owner site conduct jointly finance soil remediation work work plan approve njdep ask company contribute cost remediation company discussion njdep site owner potentially responsible party scope cost work require address know condition concern recently offer negotiate school board township term cooperative funding agreement allocation process company actively investigate historic use site include company possible connection date claim assert company september njdep issue administrative enforcement directive notice new jersey spill compensation control act require company approximately company perform assessment natural resource damage implement unspecified interim remedial measure restore condition low passaic river directive allege company liable historically send bulk waste inland chemical company facility newark reprocess release hazardous substance facility migrate newark bay continue adverse impact low passaic river watershe subsequently epa issue notice letter comprehensive environmental response compensation liability act cercla numerous partiesbut include companyseeke cooperation study condition substantially stretch passaic river subject njdep directive group party enter consent agreement epa finance portion study epa estimate study cost million roughly half finance private party group study lead cleanup action direct epa army corps engineer company work cooperatively group party receive njdep directive andor epa notice explore potential resolution directive address risk collateral claim company believe caused contribute contamination low passaic river watershe company inform njdep willing discuss allegation company directive recent communication cooperating group njdep state responsible party cooperate njdep perform damage assessment restoration civil action recover remedial cost treble damage administrative cost penalty late group federal agency designate trustee natural resource affect contamination passaic river watershe approach cooperate group solicit interest funding cooperative study possible natural resource damage nrd area study presumably dovetail ongoing epa study ideally join njdep coordinate action njdep seek directive discussion federal trustee ongoing extent liability company face directive epa notice letter respect future nrd action claim federal trustee contribution responsible party determine october michigan department environmental quality mdeq send company letter violation lov allege unspecified period time emission certain digestion tank mead johnsons zeeland michigan facility exceed applicable limit facilitys renewable operating air permit lov require company corrective action submit compliance program report mdeq demand fine penalty enforcement action result penalty injunctive relief company contest allegation lov company mdeq work revision company air use permit predict ultimate outcome certainty permit revision resolve matter additional enforcement action need continue contest lov december company njdep enter administrative consent order aco concern allege violation new jersey air pollution control act implement regulation company new brunswick facility pursuant aco company agree submit permit application create facilitywide emission cap pay administrative fine approximately obligation satisfy early subsequently february aco amend provide company install new cogeneration turbine new brunswick facility december obtain air permit include require cogeneration turbine december estimate cost new cogeneration turbine approximately million company defendant class action suit file superior court puerto rico february resident ward municipality barceloneta allege air emission government own operate table content bristolmyer squibb company note consolidated financial statement continue note legal proceeding contingency continue wastewater treatment facility say municipality cause respiratory ailment violate local air rule company believe wastewater discharge treatment facility material compliance term company permit company believe litigation resolve immaterial suit year old initial stage issue class certification pende event adverse judgment company ultimate financial liability great anticipate company responsible state federal foreign law include cercla certain cost investigate remediate contamination result past industrial activity company current site waste disposal reprocess facility operate party company typically estimate cost base information obtain epa counterpart state agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party prp company accrue liability probable reasonably estimable december company estimate share total future cost site approximately million million respectively record liability represent sum good estimate simple estimate reasonably estimate minimal probable range cost take account potential recovery party currently expect company pay million exclude legal fee year investigation remediation matter include liability cercla onsite remedial obligation possible predict certainty outcome environmental proceeding ultimate cost remediation company believe reasonably possible expenditure company incur excess exist reserve material adverse effect business financial position result operation matter october sec notify company conduct informal inquiry activity certain company german pharmaceutical subsidiary employee andor agent company believe secs informal inquiry encompass matter currently investigation staatsanwaltin prosecutor munich german uncertain time company believe inquiry investigation concern potential violation foreign corrupt practice act andor german law company cooperate sec german authority possible time reasonably assess final outcome matter reasonably estimate possible loss range loss company conduct internal review pharmaceutical operation mexico total sale million month end december broad review include area compliance legal financial regulatory requirement company standard business conduct ethic review ongoing time company unable assess impact result investigation company indemnification officer director companys corporate bylaw require extent permit law company shall indemnify officer director judgments fine penalty amount pay settlement include legal fee appeal incur connection civil criminal action proceeding relate service company subsidiary bylaw provide limit indemnification indemnification permit case willful misconduct know violation criminal law improper personal benefit permit law state delaware company year purchase director officer insurance coverage cover claim director officer amount type coverage varied period period dictate market condition excess policy provide additional coverage litigation matter regulatory action describe involve certain company current director officer cover aforementioned indemnity applicable certain prior period insurance policy certain indemnification payment cover company director officer insurance coverage company predict certainty extent company recover insurer indemnification payment connection litigation matter regulatory action describe july company insurer federal insurance company federal file lawsuit new york supreme court company current officer member board director seek rescission alternative declaration allow federal avoid payment certain director officer insurance policy certain fiduciary liability insurance policy respect potential liability arise connection matter describe vanlev litigation security matter erisa litigation section discovery take matter party currently engage discussion potential settlement action october companys insurer international business insurance ltd sri inform table content bristolmyers squibb company note consolidated financial statement continue note legal proceeding contingency continue company intend try avoid certain insurance policy issue company ground allege material misrepresentation nondisclosure initiate arbitration proceeding london england sri indicate intend rely allegation similar describe security matter section support avoidance action note subsequent event january company announce plan divest canadian consumer medicine business year end december sale consumer medicine brand canada total approximately million company consumer medicine business japan asia pacific latin america europe middle east africa include plan divestiture november company medarex inc medarex enter worldwide collaboration develop commercialize mdx fully human antibody investigational product target ctla receptor mdx develop medarex currently phase iii clinical development treatment metastatic melanoma collaboration agreement effective january time company cash payment million medarex expense research development additional million equity investment medarex note select quarterly financial datum unaudite second fourth quarter quarter quarter quarter year dollar million share datum net sale gross margin earning continue operation discontinue operation net net earning earning common share basic earning continue operation discontinue operation net net earning dilute earning continue operation discontinue operation net net earning dividend declare common share cash cash equivalent marketable security net sale gross margin earning continue operation discontinue operation net net earning table content bristolmyers squibb company note consolidated financial statement continue earning common share basic earning continue operation discontinue operation net net earning dilute earning continue operation discontinue operation net net earning dividend declare common share cash cash equivalent marketable security note earning share quarter add amount year period compute discrete basis include litigation charge million million million second fourth quarter respectively second quarter include litigation settlement income million second fourth quarter include gain sale mead johnson adult nutritional business million million million million respectively second fourth quarter include provision restructure item million million million million respectively second fourth quarter include upfront payment license agreement million million million million respectively second quarter include writeoff acquire process research development million million respectively include litigation settlement charge million million second fourth quarter respectively second quarter include litigation settlement income million million million respectively second fourth quarter include provision restructure item million million million million respectively second fourth quarter include reversal prior period restructure item million million million respectively fourth quarter include upfront payment license agreement million million respectively common equivalent share exclude computation dilute earning share effect antidilutive follow million second fourth quarter quarter quarter quarter year table content report independent register public accounting firm board director stockholder bristolmyers squibb company complete integrate audit bristolmyer squibb company company consolidated financial statement internal control financial reporting december audits consolidated financial statement accordance standard public company accounting oversight board united states opinion base audit present consolidated financial statement financial statement schedule opinion consolidated financial statement list accompany index present fairly material respect financial position company subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america addition opinion financial statement schedule list accompany index present fairly material respect information set forth read conjunction relate consolidated financial statement financial statement financial statement schedule responsibility company management responsibility express opinion financial statement financial statement schedule base audit conduct audits statement accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion internal control financial reporting opinion management assessment include management report internal control financial reporting appear item company maintain effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso fairly state material respect base criterion furthermore opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion management assessment effectiveness company internal control financial reporting base audit conduct audit internal control financial reporting accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit internal control financial reporting include obtain understand internal control financial reporting evaluate management assessment testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp pricewaterhousecooper llp philadelphia march table content item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule base evaluation management conclude december disclosure control procedure effective provide reasonable assurance company record process summarize report information company disclose report company file submit securities exchange act amend time period specify sec rule form management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp pwc independent register public accounting firm audit company financial statement include report issue report management assessment effectiveness company internal control financial reporting december include status previously disclose internal control item make evaluation effectiveness design operation disclosure control procedure management consider significant resource devote substantial action take company past year remediate reportable condition define standard establish american institute certify public accountant relate internal control financial reporting income taxis initially identify communicate company audit committee pwc connection audit company consolidate financial statement year end december repeat year end december reportable condition identify pwc need enhance income tax accounting function provide timely analysis reconciliation income tax provision relate income tax asset liability action take company include engage outside consultant assist company personnel conduct comprehensive detailed review certain company income tax reporting account company continue strengthen internal control financial reporting income taxis effort include continue work outside consultant make significant personnel change include hire new vice president tax increase number tax department key personnel implement policy procedure enhance communication business unit tax department financial reporting personnel ensure comprehensive appropriate timely review matter implement new update exist tax accounting policy provide training policy base evaluation chief executive officer chief financial officer conclude december internal control financial reporting income taxis issue sufficiently remediate discuss item financial statementsnote legal proceeding contingency management identify need remediate deficiency internal control methodology process calculate price report governmental rebate pricing program relate pharmaceutical business conduct evaluation chief executive officer chief financial officer consider substantial effort undertake company remediate internal control deficiency include retain outside consultant subject matter expertise conduct exhaustive review exist methodology process train employee implementation revise methodology process base review chief executive officer chief financial officer conclude company internal control methodology process calculate price describe sufficiently remediate table content change internal control financial reporting change companys internal control financial reporting quarter end december materially affect reasonably likely materially affect company internal control financial reporting table content iii item director executive officer registrant reference proxy statement file march respect director registrant incorporate reference hereof response information require item information require item respect executive officer registrant include reliance general instruction instruction item regulation item executive compensation reference proxy statement file march respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management reference proxy statement file march respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement file march respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement file march respect auditor fee incorporate reference hereof response information require item table content item exhibit financial statement schedule number consolidated financial statement note consolidated financial statement report independent register public accounting firm financial statement schedule valuation qualifying account schedule include additional financial datum omit applicable require information include financial statement note thereto exhibit list exhibit list identify number correspond exhibit table item regulation exhibit designate asterisk management contract compensatory plan arrangement require file pursuant item indicate exhibit commission file number restate certificate incorporation bristolmyer squibb company incorporate reference exhibit form quarterly period end september bylaw bristolmyers squibb company amend january file herewith letter agreement date march incorporate reference exhibit fiscal year end december indenture date june bristolmyers squibb company jpmorgan chase bank successor trustee chase manhattan bank national association incorporate reference exhibit form date file june form debenture bristolmyers squibb company incorporate reference exhibit form date file june form debenture bristolmyers squibb company incorporate reference exhibit fiscal year end december form debenture bristolmyers squibb company incorporate reference exhibit form quarterly period end september year competitive advance revolve credit facility agreement date december bristolmyers squibb company borrowing subsidiary lender name agreement bank america syndication agent jpmorgan chase bank citicorp north america inc administrative agent file herewith second supplemental indenture date september bristolmyers squibb company jpmorgan chase bank successor trustee chase manhattan bank indenture date june previously file exhibit annual report form note form note bristolmyer squibb company incorporate reference exhibit fiscal year end december supplemental indenture date august bristolmyer squibb company jpmorgan chase bank trustee indenture date june incorporate reference exhibit form quarterly period end september purchase agreement date august bristolmyer squibb company goldman sachs morgan securities inc representative purchaser name schedule agreement senior note senior note incorporate reference exhibit form quarterly period end september table content exchange registration right agreement date august bristolmyer squibb company goldman sachs morgan securities inc representative purchaser name schedule purchase agreement senior note senior note incorporate reference exhibit form quarterly period end september form senior note incorporate reference exhibit form quarterly period end september incorporate reference exhibit form quarterly period end september form senior note incorporate reference exhibit form quarterly period end september indenture date october bristolmyer squibb company issuer jpmorgan chase bank trustee incorporate reference exhibit form quarterly period end september registration right agreement date october bristolmyer squibb company goldman sachs morgan securities inc representative purchaser name schedule purchase agreement float rate convertible senior debenture incorporate reference exhibit form quarterly period end september form float rate convertible senior debenture incorporate reference exhibit form quarterly period end september purchase agreement date september bristolmyer squibb company goldman sachs morgan securities inc representative purchaser name schedule purchase agreement float rate convertible debenture incorporate reference exhibit form quarterly period end september specimen certificate common stock incorporate reference exhibit fiscal year end december speciman certificate convertible prefer stock incorporate reference exhibit fiscal year end december bristolmyers squibb company stock incentive plan effective amend effective july incorporate reference exhibit form quarterly period end june bristolmyers squibb company stock incentive plan effective amend effective july incorporate reference exhibit form quarterly period end june bristolmyers squibb company teamshare stock option plan amend restate effective september incorporate reference exhibit fiscal year end december bristolmyers squibb company executive performance incentive plan effective january incorporate reference exhibit fiscal year end december bristolmyers squibb company executive performance incentive plan effective january incorporate reference exhibit proxy statement date april bristolmyers squibb company stock option plan amend restate october file herewith bristolmyers squibb company performance incentive plan amend adopt incorporate reference exhibit fiscal year end december amend january incorporate reference exhibit fiscal year end december amend april incorporate reference exhibit fiscal year end december amend effective january incorporate reference exhibit fiscal year end december amend effective january incorporate reference exhibit fiscal year end december table content benefit equalization plan bristolmyer squibb company subsidiary affiliate corporation participate bristolmyer squibb company retirement income plan bristolmyers squibb puerto rico inc retirement income plan amend amend restate january amend effective october incorporate reference exhibit fiscal year end december amend effective february incorporate reference exhibit fiscal year end december benefit equalization plan bristolmyer squibb company subsidiary affiliate corporation participate bristolmyer squibb company saving investment program amend restate effective january incorporate reference exhibit fiscal year end december squibb corporation supplementary pension plan amend previously amend restate incorporate reference exhibit fiscal year end december amend september incorporate reference exhibit fiscal year end december bristolmyers squibb company retirement income plan nonemployee director amend march incorporate reference exhibit fiscal year end december bristolmyers squibb company defer compensation plan nonemployee director amend january file herewith bristolmyers squibb company nonemployee directors stock option plan amend approve stockholder incorporated reference exhibit registration statement form amend incorporate reference exhibit fiscal year end december amend january incorporate reference exhibit fiscal year end december bristolmyer squibb company nonemployee directors stock option plan amend approve stockholder incorporated reference exhibit proxy statement date march squibb corporation deferral plan fee outside director amend adopt incorporate reference exhibit squibb corporation fiscal year end december file amend effective december incorporate reference exhibit fiscal year end december amendment company plan agreement legal document writing pursuant action board director october reflect change company bristolmyer squibb company incorporate reference exhibit form fiscal year end december form agreement enter bristolmyer squibb company name executive officer certain executive effective january file herewith statement computation ratio file herewith subsidiary registrant file herewith consent pricewaterhousecooper llp file herewith section certification letter file herewith section certification letter file herewith section certification letter file herewith section certification letter file herewith indicate brand name product register trademark own company subsidiary erbitux trademark imclone avapro aprovel avalide plavix trademark sanofisynthelabo glucophage glucovance trademark merck sante sas associate merck kgaa darmstadt germany abilify trademark otsuka pharmaceuticals ltd moisturel duricef trademark galen chemicals limited javlor trademark pierre fabre medicament truvada trademark gilead sciences inc emsam trademark somerset pharmaceuticals inc table content signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize bristolmyers squibb company registrant peter dolan peter dolan chairman board director chief executive officer date march pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date peter dolan chairman board director chief executive march officer principal executive officer peter dolan andrew bonfield senior vice president chief financial officer principal march financial officer andrew bonfield david zabor vice president controller principal accounting officer march david zabor robert allen director march robert allen lewis campbell director march lewis campbell vance coffman director march vance coffman james cornelius director march james cornelius ellen futter director march ellen futter louis gerstner director march louis gerstner laurie glimcher director march laurie glimcher leif johansson director march leif johansson james robinson iii director march james robinson iii louis sullivan director march louis sullivan table content exhibit index